Skip to content
buyWeak

Michael W. Dunne bought $2,191 of ITRM

director at Iterum Therapeutics plc. 6,000 shares at an average of $0.37, traded Nov 18, 2025, filed Nov 20, 2025.

Conviction score
15
Value
$2,191
6,000 shares
Holdings after
241,001
+3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $2k at market
    0
  • Relative to holdings
    Holdings up 2.6%
    0
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001193125-25-288848, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 18, 2025POpen-market purchase
Ordinary Shares
+6,000$0.37$2,191241,001Nov 20, 2025

Related signals

Other insiders at Iterum Therapeutics plc and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
18Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$11k
15,000 shares
+7%
32Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$35k
25,000 shares
+28%
23Weak
ITRMbuy
Iterum Therapeutics plc
Michael W. Dunne
director
$18k
10,000 shares
+13%
35Weak
ITRMbuy 2
Iterum Therapeutics plc
Michael W. Dunne
director
$41k
20,000 shares
+34%
39Weak
ITRMbuy 2
Iterum Therapeutics plc
Corey N. Fishman
Chief Executive Officer
$16k
10,000 shares
+22%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Michael W. Dunne bought $2,191 of ITRM | InsiderTell